Simple Summary To improve overall survival (OS), we evaluated a combination of
cetuximab and nivolumab for toxicity and efficacy in patients with incurable recurrent and/or …

Purpose: A phase II multi-institutional clinical trial was conducted to determine overall
survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous …

Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …

PURPOSE CheckMate 651 (ClinicalTrials. gov identifier: NCT02741570) evaluated first-line
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …

Summary Background Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are
active as single agents and in combination with cytotoxic chemotherapy for recurrent or …

Background After the introduction of ICI treatment, data about feasibility and activity of a
cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and …

PURPOSE Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in
recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc …

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in
2017? - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …

Introduction: The majority of patients with locally advanced head and neck squamous cell
carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M …

Simple Summary Immunotherapy has made a breakthrough in the treatment of patients with
recurrent and/or metastatic head and neck squamous cell carcinoma in the second line …